Altimmune, Inc. (NASDAQ: ALT) reported Q3 EPS of ($0.48), $0.01 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $2 thousand versus the consensus estimate of $867.83 thousand.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.